Patents by Inventor Sai-Wen Tang

Sai-Wen Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • A NOVEL CD16+ NATURAL KILLER CELL AND A METHOD OF CULTURING CD16+ NATURAL KILLER CELL
    Publication number: 20230036481
    Abstract: The present invention provides a human CD16+ natural killer cell line and a CAR-expressing human CD16+ natural killer cell line. These human CD16+ natural killer cell line and a CAR-expressing human CD16+ natural killer cell line does not include synthetic, genetically modified or purposely deliberately delivered polynucleotide encoding the CD16 receptor and are non-tumorigenic cell lines. Therefore, this human CD16+ natural killer cell line and a CAR-expressing human CD16+ natural killer cell line might provide considerable long-term safety for disease treatment.
    Type: Application
    Filed: January 15, 2021
    Publication date: February 2, 2023
    Applicant: Acepodia Biotechnologies Ltd.
    Inventors: SAI-WEN TANG, ZIH-FEI CHENG, CHIA-YUN LEE, HAO-KANG LI, HSIU-PING YANG, CHING-WEN HSIAO, SEN HEN YANG, TAI-SHENG WU, YAN-LIANG LIN, YAN-DA LAI, SHIH-CHIA HSIAO
  • Systemic targeting of inflammatory sites and enhanced immunomodulatory function by introducing the chimeric antigen receptor (CAR) into mesenchymal stem cells for inflammatory and autoimmune diseases
    Patent number: 11246890
    Abstract: Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: February 15, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Tzuhua Dennis Lin, Stuart B. Goodman, Sai-Wen Tang, Everett Hurteau Meyer, Magdiel Pérez Cruz
  • REGULATORY T CELLS TARGETED WITH CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20190307795
    Abstract: Regulatory T cells (Treg) are engineered to express a chimeric antigen receptor (CAR), that specifically binds folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells. Also provided are methods for utilized engineered T regulatory cells to enhance hematopoietic cell transplantation.
    Type: Application
    Filed: January 24, 2019
    Publication date: October 10, 2019
    Inventors: Sai-Wen Tang, Panagiota Iliopoulou, Magdiel Perez Cruz, Everett Hurteau Meyer
  • SYSTEMIC TARGETING OF INFLAMMATORY SITES AND ENHANCED IMMUNOMODULATORY FUNCTION BY INTRODUCING THE CHIMERIC ANTIGEN RECEPTOR (CAR) INTO MESENCHYMAL STEM CELLS FOR INFLAMMATORY AND AUTOIMMUNE DISEASES
    Publication number: 20190298774
    Abstract: Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.
    Type: Application
    Filed: April 1, 2019
    Publication date: October 3, 2019
    Inventors: Tzuhua Dennis Lin, Stuart B. Goodman, Sai-Wen Tang, Everett Hurteau Meyer, Magdiel Pérez Cruz